NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024
These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Category
- Skin Cancers
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status
While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.
Category
- Skin Cancers
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00